ALS Phase 2 Study KNS-760704 CL201 Treatment Report : PatientsLikeMe

Filter by:

All
Start typing to see suggestions

patients

Home > Community Treatment Reports and Side Effects > ALS Phase 2 Study KNS-760704 CL201 Treatment Report

You appear to have JavaScript disabled in your browser. PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you. How do I enable JavaScript?

What is ALS Phase 2 Study KNS-760704 CL201?

NCT00647296 is a 2 part, randomized, double-blind, safety and tolerability study evaluating the drug KNS-760704 in patients with amyotrophic lateral sclerosis (ALS). The drug KNS-760704 is now known as dexpramipexole. Other study ID includes: KNS-760704-CL201. Read more...

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose	# of patients	# of patients with evaluations Efficacy
ALS (Amyotrophic Lateral Sclerosis)	3	1
Participate in clinical trial	2	1
Safety & tolerability	1	1

See all 4 patients currently using ALS Phase 2 Study KNS-760704 CL201

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe	0
Moderate	0
Mild	1
None	1

Commonly reported side effects, conditions, and hospitalizations associated with ALS Phase 2 Study KNS-760704 CL201

Dry mouth (xerostomia)	1	1

Reported Schedules

12.5 mg daily	25 mg daily	300 mg daily
1	1	2

Reported Stop Reasons

Why Patients Stopped Using ALS Phase 2 Study KNS-760704 CL201 (multiple reasons could be selected)
Reason	# Patients	Percentage of patients
Course of treatment ended	1

See all 1 patient who’ve stopped using ALS Phase 2 Study KNS-760704 CL201

Reported Duration See details about how long patients take this treatment ▼ Reported Duration Hide details ▲

Currently Using ALS Phase 2 Study KNS-760704 CL201

A bar graph

0-1 month	1-3 months	3-6 months	6 months-1year	1-2 years	2 years or more
0	0	0	0	0	1

Stopped Using ALS Phase 2 Study KNS-760704 CL201

A bar graph

0-1 month	1-3 months	3-6 months	6 months-1year	1-2 years	2 years or more
0	0	0	1	0	0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of ALS Phase 2 Study KNS-760704 CL201

Always	2	100%
Usually	0	0%
Sometimes	0	0%
Never	0	0%

Burden

Difficulty being on treatment

Burden of ALS Phase 2 Study KNS-760704 CL201

Very	0	0%
Somewhat	1	50%
A little	1	50%
Not at all	0	0%

Cost

Paid out of pocket

Cost of ALS Phase 2 Study KNS-760704 CL201

$200+	0	0%
$100-199	0	0%
$50-99	0	0%
$25-49	0	0%
< $25	2	100%

Patient Evaluations

See all 2 patient evaluations

Ya Mon

Sex: M

Bulbar: mild

Arms: severe

Chest: severe

Legs: severe
Ya Mon

300 mg daily

since Oct 24, 2009
Efficacy ?Can't tell for ALS (Amyotrophic Lateral Sclerosis)
Side Effects None
Advice/Tips This Clinical Trial is to evaluate the tolerabiltiy and effectiveness of an investigational drug. Initially a double blind placebo-controlled study, the res... See full evaluation

See all 2 patient evaluations

Report created on February 11, 2012.

PatientsLikeMe ™